Literature DB >> 2496167

Alternatively spliced mRNA encodes a secreted form of human CD8 alpha. Characterization of the human CD8 alpha gene.

A M Norment1, N Lonberg, E Lacy, D R Littman.   

Abstract

We have determined the organization and nucleotide sequence of the gene encoding the human T cell surface glycoprotein CD8 alpha. This gene spans approximately 8 kb and is organized into six exons which encode separate functional domains of the protein. Exon 1 encodes the 5' untranslated region and leader peptide, exon II the Ig V-like region, exon III the hinge-like region, exon IV the transmembrane domain, and exons V and VI the cytoplasmic tail. Alternative splicing that excludes nucleotide sequences from exon IV results in a transcript which encodes a secreted form of the protein. This transcript accounts for approximately 15% of the total CD8 alpha mRNA in human T cell leukemia lines and in normal human tissues. Secreted CD8 alpha protein can be detected in culture supernatants of T cell leukemia lines and PHA-stimulated PBMC by immunoprecipitation with the anti-CD8 alpha mAb OKT8 or with a polyclonal rabbit antiserum specific for the 28 amino acid cytoplasmic domain of CD8 alpha. The secreted CD8 alpha protein forms homodimers; when analyzed by SDS-PAGE, the protein migrates with an apparent molecular mass of 27 or 54 kDa under reducing or non-reducing conditions, respectively. Human secreted CD8 alpha may serve an immunoregulatory role for the interactions of T cells with their targets in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Phylogenetic and developmental study of CD4, CD8 α and β T cell co-receptor homologs in two amphibian species, Xenopus tropicalis and Xenopus laevis.

Authors:  Asiya Seema Chida; Ana Goyos; Jacques Robert
Journal:  Dev Comp Immunol       Date:  2010-11-21       Impact factor: 3.636

2.  Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2.

Authors:  A J Capobianco; P Zagouras; C M Blaumueller; S Artavanis-Tsakonas; J M Bishop
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  Structure of CD8 alpha and beta chains of the orangutan: novel patterns of mRNA splicing encoding hingeless polypeptides.

Authors:  D A Lawlor; P Parham
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.

Authors:  R Harpaz; R Edelman; S S Wasserman; M M Levine; J R Davis; M B Sztein
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  High serum levels of CD8 antigen in primary biliary cirrhosis: a possible cause of suppressor cell dysfunction?

Authors:  K T Nouri Aria; M Lombard; R Williams
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Structure and expression of the gene encoding CD8 alpha chain (Leu-2/T8).

Authors:  K Nakayama; S Tokito; K Okumura; H Nakauchi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Soluble CD8 in patients with rheumatic diseases.

Authors:  J A Symons; N C Wood; F S di Giovine; G W Duff
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

8.  Phosphorylation and down-regulation of CD4 and CD8 in human CTLs and mouse L cells.

Authors:  J P DiSanto; J S Klein; N Flomenberg
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

9.  CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

Authors:  G C de Gast; I A Haagen; A A van Houten; S C Klein; A J Duits; R A de Weger; T M Vroom; M R Clark; J Phillips; A J van Dijk
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

10.  Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4.

Authors:  M E Lenburg; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.